tiprankstipranks
Advertisement
Advertisement

HK:0013 Stock Latest News

HUTCHMED Publishes 2025 Annual Report and Sets Hybrid 2026 AGM
Company AnnouncementsHUTCHMED Publishes 2025 Annual Report and Sets Hybrid 2026 AGM
16h ago
HUTCHMED Sets 2026 AGM With New Share Issuance and Buyback Mandates
PremiumCompany Announcements
HUTCHMED Sets 2026 AGM With New Share Issuance and Buyback Mandates
16h ago
HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026
PremiumCompany Announcements
HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026
1d ago
HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients
PremiumCompany Announcements
HUTCHMED Launches Phase III Trial of BTK Inhibitor HMPL-760 in Chinese Lymphoma Patients
18d ago
HUTCHMED CEO’s Long-Term Incentive Share Awards Vest
PremiumCompany Announcements
HUTCHMED CEO’s Long-Term Incentive Share Awards Vest
25d ago
HUTCHMED Vests 726,317 LTIP Shares to Top Executives After 2025 Results
PremiumCompany AnnouncementsHUTCHMED Vests 726,317 LTIP Shares to Top Executives After 2025 Results
30d ago
Hutchmed price target lowered to $20 from $21 at BofA
Premium
The Fly
Hutchmed price target lowered to $20 from $21 at BofA
1M ago
HCM
Hutchmed discontinues all active tazemetostat clinical trials
Premium
The Fly
Hutchmed discontinues all active tazemetostat clinical trials
1M ago
HCM
HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move
PremiumCompany Announcements
HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move
1M ago
Hutchmed price target lowered to $21 from $22 at BofA
PremiumThe Fly
Hutchmed price target lowered to $21 from $22 at BofA
1M ago
HCM
HUTCHMED reshapes board leadership as veteran independent director plans retirement
PremiumCompany Announcements
HUTCHMED reshapes board leadership as veteran independent director plans retirement
1M ago
HUTCHMED Publishes 2025 Form 20-F for Investors
PremiumCompany Announcements
HUTCHMED Publishes 2025 Form 20-F for Investors
1M ago
HUTCHMED Posts Strong 2025 Profit as ATTC Pipeline and Global Oncology Portfolio Advance
PremiumCompany AnnouncementsHUTCHMED Posts Strong 2025 Profit as ATTC Pipeline and Global Oncology Portfolio Advance
1M ago
HUTCHMED launches global early-stage trial for novel ATTC cancer therapy HMPL-A580
Premium
Company Announcements
HUTCHMED launches global early-stage trial for novel ATTC cancer therapy HMPL-A580
1M ago
HUTCHMED Sets March 5 Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
HUTCHMED Sets March 5 Board Meeting to Approve 2025 Annual Results
2M ago
Hutchmed reports publication of SACHI results in The Lancet
PremiumThe Fly
Hutchmed reports publication of SACHI results in The Lancet
3M ago
AZN
HCM
HUTCHMED’s Savolitinib Combo Shows Phase III Success in EGFR-Mutated Lung Cancer
PremiumCompany Announcements
HUTCHMED’s Savolitinib Combo Shows Phase III Success in EGFR-Mutated Lung Cancer
3M ago
HUTCHMED’s Sovleplenib Hits Phase III Goal in Warm Autoimmune Hemolytic Anemia Trial in China
PremiumCompany Announcements
HUTCHMED’s Sovleplenib Hits Phase III Goal in Warm Autoimmune Hemolytic Anemia Trial in China
3M ago
Hutchmed says Phase III of ESLIM-02 trial met primary endpoint
PremiumThe Fly
Hutchmed says Phase III of ESLIM-02 trial met primary endpoint
3M ago
HCM
Hutchmed price target lowered to $22 from $25 at BofA
PremiumThe FlyHutchmed price target lowered to $22 from $25 at BofA
3M ago
HCM
Hutchmed initiates Phase III stage of Phase II/III trial
Premium
The Fly
Hutchmed initiates Phase III stage of Phase II/III trial
3M ago
HCM
Hutchmed initiates Phase III stage of Phase II/III trial
Premium
The Fly
Hutchmed initiates Phase III stage of Phase II/III trial
3M ago
HCM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >